Table 1.
Option A | Option B | Option B+ | |
---|---|---|---|
Mother (CD4≤350 cells/mm3) | Triple ARVs, starting from diagnosis and continued for life | Triple ARVs, starting from diagnosis and continued for life | Triple ARVs regardless of CD4 count, starting from diagnosis and continued for life |
Mother (CD4>350 cells/mm3) | Prophylaxis: Antepartum: AZT from 14 weeks gestation Intrapartum: sd NVP at onset of labour and AZT/3TC Postpartum: AZT/3TC for seven days |
Prophylaxis: Triple ARVs from 14 weeks gestation until one week after exposure to breastmilk has ended |
|
Infant | NVP (daily) from birth until one week after cessation of breastfeeding, or until age four to six weeks if replacement feeding | NVP or AZT (daily) from birth until age four to six weeks (regardless of infant feeding method) | NVP or AZT (daily) from birth until age four to six weeks (regardless of infant feeding method) |
Adapted from ref. [5].
ARV=antiretroviral; AZT=azidothymidine; NVP=nevirapine; sd=single-dose.